[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Psyched_Alpha Psychedelic Alpha
Psychedelic Alpha posts on X about atai life, investment, has been the most. They currently have XXXXXX followers and XXX posts still getting attention that total X engagements in the last XX hours.
Engagements: undefined #
- X Week XXXXX -XX%
- X Month XXXXXX -X%
- X Months XXXXXXX +279%
- X Year XXXXXXX -XXXX%
Mentions: undefined #
- X Month XX +9.10%
- X Months XX +179%
- X Year XX +91%
Followers: XXXXXX #
- X Week XXXXXX +0.10%
- X Month XXXXXX +0.51%
- X Months XXXXXX +3.20%
- X Year XXXXXX +2.80%
CreatorRank: undefined #
Social Influence #
Social category influence stocks finance
Social topic influence atai life, investment, has been
Top assets mentioned ATAI Life Sciences (ATAI)
Top Social Posts #
Top posts by engagements in the last XX hours
"atai Life Sciences Phase 2b trial of its non-psychedelic candidate inidascamine (RL-007) in patients with cognitive impairment associated with schizophrenia failed to meet statistical significance on the primary endpoint. The company will not fund further development of the candidate and described the company developing RL-007 Recognify Life Sciences as a strategic investment (according to filings atai owns the majority of the company). Company execs shrugged off the miss emphasising their commitment to their psychedelics compounds. Indeed while atai emphasised its hub-and-spoke model that"
X Link @Psyched_Alpha 2025-08-08T13:52Z 20.6K followers, 1712 engagements
"atai Life Sciences and Beckley Psytech have shared topline data from a Phase 2a open-label study of intranasal 5-MeO-DMT (BPL-003) that saw patients with treatment-resistant depression receive an X mg dose followed by a XX mg dose two weeks later. The data represents XX patients. Read more in Bulletin 209:"
X Link @Psyched_Alpha 2025-09-24T19:47Z 20.6K followers, 1641 engagements
"Last week atai Life Sciences announced that it has been awarded a UG3/UGH grant from NIDA to optimise and develop a suite of non-hallucinogenic 5-HT2A/2C receptor agonists for opioid use disorder (OUD). Read more in Bulletin 209:"
X Link @Psyched_Alpha 2025-09-29T19:48Z 20.6K followers, XXX engagements
"Can psychedelics improve your mental health Dr James Rucker speaks with @DoctorChrisVT and @xandvt for BBC Radio 4"
X Link @Psyched_Alpha 2025-10-01T15:28Z 20.6K followers, 3257 engagements